Thorsten is a biopharma executive and industry veteran with a wealth of knowledge and
almost 30 years of expertise in all areas of the business.
His strong intercultural background paired with long term international leadership
experience makes Thorsten a business sensitive and empathic partner of all ILSC clients.
„Building rapport and trust is a key element of successful consulting assignments
and a key success factor for young entrepreneurs as well as the experienced managers
among our clients“. „We before me” is the underlying strong principle that has become the
guard rail of Thorsten’s career and business acumen.
More recently, Thorsten has served as the Global Head Medical Affairs at Immunomedics
Inc., Morris Plains, New Jersey, where he successfully built the global medical affairs
structure of the company, and together with his team established a competitive IIT
program, a world class scientific communication department, global medical information,
and a best-in-class MSL team. This high-performing team strongly supported the launch of
the first in class antibody drug conjugate sacituzumab govitecan
(TRODELVY™) in triple
negative breast cancer and urothelial cancer. Moreover, based on creative IITs the team
initiated and facilitated the FDA’s Orphan Drug Designation of sacituzumab govitecan in
GBM. In late 2020 Thorsten left Immunomedics and returned to Europe, when the company was
acquired by Gilead Science.
Prior to Immunomedics, Thorsten served at Celgene Corporation, Summit, New Jersey, for
almost 13 years in various national and international roles, such as Executive Director US
Medical Affairs and Disease Lead Multiple Myeloma, Director Oncology, Director New
Indications, Director Clinical Research Central Europe, Middle East and Africa, and
Associate Director Medical Affairs and founding father of Celgene Germany.
Before joining Celgene, Thorsten was the marketing lead for dasatinib (Sprycel®) at BMS
in Germany, Head of Marketing at MSO, a subsidiary of Schering AG, served AMGEN for
10 years in multiple roles in both Hematology, Oncology and HIV.
Throughout his career, Thorsten was directly involved in the successful launches of
multiple blockbuster drugs, including but not limited to Neupogen®, Aranesp®, MabCampath®,
Zevalin®, Sprycel®, Revlimid®, Vidaza®, Abraxane®, and Trodelvy™,
in multiple indications in both hematology and oncology, and in various markets.
Thorsten holds a Master of Science in Molecular Biology with honors, and a Bachelor of
Science in Biology, studied histology, molecular biology and microbial genetics at Clarion
University of Pennsylvania, USA, and is a certified organizational change manager of V.iT.
GmbH, Germany.
He holds a certificate in Strategic Management for Executives of the St. Galler Business
School, Switzerland.
He received multiple awards for his work excellence and is one of eight nominees of the
John W. Jackson Leadership Award, 2016.
Thorsten is married with four children and meanwhile lives in Münster, Germany.
INQUIRE
